MEI Pharma is a San Diego-based clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies.
Its pipeline candidates target pathways involved in hematological malignancies and/or solid tumors.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
Zandelisib is in multiple ongoing clinical trials evaluating patients with B-cell malignancies, intended to support marketing approvals in the United States and globally.
Source: LinkedIn company description · Retrieved October 13, 2026
Voruciclib is being explored in combination with standard therapies for hematologic malignancies and solid tumors.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Open the published source list.RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 14, 2026, September 15, 2026, September 16, 2026, September 18, 2026, September 19, 2026, September 21, 2026, September 28, 2026 and October 8, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.